A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
DRUG: Camrelizumab„ÄÅRivoceranib|DRUG: Camrelizumab
Recurrence-Free Survival (RFS), as Determined by the investigator, RFS is defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by the investigator, or death from any cause (whichever occurs first)., Randomization up to approximately 43 months
RFS Rate at 24 and 36 Months, as Assessed by the Investigator, Randomization up to 24 months and up to 36 months|Time to Recurrence (TTR) as determined by the investigator, TTR defined as the time from randomization to first documented occurrence of local, regional, or metastatic HCC., Randomization up to approximately 43 months|Overall Survival (OS), OS is defined as the time from randomization to death from any cause., Randomization up to approximately 43 months|The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0, Randomization up to approximately 43 months
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.